Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsy

Background: To enhance prostate cancer diagnosis, multiparametric Magnetic Resonance Imaging (mpMRI) combined with Transrectal Ultrasound (TRUS) fusion-guided biopsy has emerged as a promising technique. This study aimed to evaluate its clinical benefits over traditional TRUS-guided biopsy. Methods:...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen Ying, Yongbo Wang, Jianping Wang, Minghuang Rao, Chao Li, Yongchao Wang, Yujian Huang
Format: Article
Language:English
Published: MRE Press 2025-01-01
Series:Journal of Men's Health
Subjects:
Online Access:https://oss.jomh.org/files/article/20250124-466/pdf/JOMH2024081401.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850196306185682944
author Chen Ying
Yongbo Wang
Jianping Wang
Minghuang Rao
Chao Li
Yongchao Wang
Yujian Huang
author_facet Chen Ying
Yongbo Wang
Jianping Wang
Minghuang Rao
Chao Li
Yongchao Wang
Yujian Huang
author_sort Chen Ying
collection DOAJ
description Background: To enhance prostate cancer diagnosis, multiparametric Magnetic Resonance Imaging (mpMRI) combined with Transrectal Ultrasound (TRUS) fusion-guided biopsy has emerged as a promising technique. This study aimed to evaluate its clinical benefits over traditional TRUS-guided biopsy. Methods: A retrospective analysis was performed on 83 patients diagnosed between January 2022 and April 2024. Patients were divided into two groups: 41 underwent mpMRI/TRUS fusion-guided biopsy, while 42 had traditional TRUS-guided biopsy. The baseline characteristics of both groups were similar, facilitating a direct comparison of diagnostic efficacy and complication rates. Results: The fusion-guided group showed a significantly higher detection rate of clinically significant prostate cancer (21/41 vs. 12/42, p = 0.035). It also detected more clinically significant cases (20/41 vs. 11/42, p = 0.033). Notably, the fusion group experienced fewer complications, including no instances of hematochezia (p = 0.003) or infections (p = 0.012), and reported lower postoperative pain levels (Visual Analog Scale score 1.8 ± 0.78 vs. 2.33 ± 1.07, p = 0.012). Conclusions: The integration of mpMRI with TRUS in fusion-guided biopsy enhances the accuracy of detecting clinically significant prostate cancer, reduces procedural complications, and minimizes patient discomfort. This approach represents a significant advancement in prostate cancer management, improving both diagnostic outcomes and patient safety.
format Article
id doaj-art-772666beebbb45e1a3220bfa52653039
institution OA Journals
issn 1875-6867
1875-6859
language English
publishDate 2025-01-01
publisher MRE Press
record_format Article
series Journal of Men's Health
spelling doaj-art-772666beebbb45e1a3220bfa526530392025-08-20T02:13:31ZengMRE PressJournal of Men's Health1875-68671875-68592025-01-01211818610.22514/jomh.2025.008S1875-6867(25)00325-2Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsyChen Ying0Yongbo Wang1Jianping Wang2Minghuang Rao3Chao Li4Yongchao Wang5Yujian Huang6Xiamen Haicang Hospital, 361000 Xiamen, Fujian, ChinaCixi Biomedical Research Institute, Wenzhou Medical University, 325000 Wenzhou, Zhejiang, ChinaXiamen Haicang Hospital, 361000 Xiamen, Fujian, ChinaXiamen Haicang Hospital, 361000 Xiamen, Fujian, ChinaXiamen Haicang Hospital, 361000 Xiamen, Fujian, ChinaXiamen Haicang Hospital, 361000 Xiamen, Fujian, ChinaThe First Hospital of Putian City, 351100 Putian, Fujian, ChinaBackground: To enhance prostate cancer diagnosis, multiparametric Magnetic Resonance Imaging (mpMRI) combined with Transrectal Ultrasound (TRUS) fusion-guided biopsy has emerged as a promising technique. This study aimed to evaluate its clinical benefits over traditional TRUS-guided biopsy. Methods: A retrospective analysis was performed on 83 patients diagnosed between January 2022 and April 2024. Patients were divided into two groups: 41 underwent mpMRI/TRUS fusion-guided biopsy, while 42 had traditional TRUS-guided biopsy. The baseline characteristics of both groups were similar, facilitating a direct comparison of diagnostic efficacy and complication rates. Results: The fusion-guided group showed a significantly higher detection rate of clinically significant prostate cancer (21/41 vs. 12/42, p = 0.035). It also detected more clinically significant cases (20/41 vs. 11/42, p = 0.033). Notably, the fusion group experienced fewer complications, including no instances of hematochezia (p = 0.003) or infections (p = 0.012), and reported lower postoperative pain levels (Visual Analog Scale score 1.8 ± 0.78 vs. 2.33 ± 1.07, p = 0.012). Conclusions: The integration of mpMRI with TRUS in fusion-guided biopsy enhances the accuracy of detecting clinically significant prostate cancer, reduces procedural complications, and minimizes patient discomfort. This approach represents a significant advancement in prostate cancer management, improving both diagnostic outcomes and patient safety.https://oss.jomh.org/files/article/20250124-466/pdf/JOMH2024081401.pdfmultiparametric magnetic resonance imagingtransrectal ultrasoundtransperineal prostate biopsyprostate cancer
spellingShingle Chen Ying
Yongbo Wang
Jianping Wang
Minghuang Rao
Chao Li
Yongchao Wang
Yujian Huang
Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsy
Journal of Men's Health
multiparametric magnetic resonance imaging
transrectal ultrasound
transperineal prostate biopsy
prostate cancer
title Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsy
title_full Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsy
title_fullStr Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsy
title_full_unstemmed Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsy
title_short Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsy
title_sort clinical study on mpmri trus software fusion guided transperineal prostate biopsy
topic multiparametric magnetic resonance imaging
transrectal ultrasound
transperineal prostate biopsy
prostate cancer
url https://oss.jomh.org/files/article/20250124-466/pdf/JOMH2024081401.pdf
work_keys_str_mv AT chenying clinicalstudyonmpmritrussoftwarefusionguidedtransperinealprostatebiopsy
AT yongbowang clinicalstudyonmpmritrussoftwarefusionguidedtransperinealprostatebiopsy
AT jianpingwang clinicalstudyonmpmritrussoftwarefusionguidedtransperinealprostatebiopsy
AT minghuangrao clinicalstudyonmpmritrussoftwarefusionguidedtransperinealprostatebiopsy
AT chaoli clinicalstudyonmpmritrussoftwarefusionguidedtransperinealprostatebiopsy
AT yongchaowang clinicalstudyonmpmritrussoftwarefusionguidedtransperinealprostatebiopsy
AT yujianhuang clinicalstudyonmpmritrussoftwarefusionguidedtransperinealprostatebiopsy